HDFC Securities' research report on Hindustan Unilever
HUL clocked revenue growth of 4% YoY, primarily led by the GSK acquisition. Its domestic consumer business (ex-GSK) saw a decline of 7% YoY. Growth in the Hygiene & Nutrition business (80% mix) was resilient at 6% YoY, while discretionary (15% mix)/OOH (5% mix) declined by 45/69% YoY. Gross margin dipped 222bps YoY, despite GSK being GM accretive and soft crude basket. However, cost management initiatives supported the EBITDA margin. The company saw sequential improvement in demand in May and June, but overall sentiment remains weak on account of job losses and return of lockdowns in several states. The Discretionary and OOH categories are expected to remain weak in FY21. We maintain our below-consensus EPS estimate for FY21/FY22/FY23.
OutlookWe value HUL at 50x P/E on Jun- 22E EPS and derive a target price of Rs 2,016. Maintain REDUCE on a muted absolute growth trajectory and unfavourable risk-reward.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.